Welcome to our dedicated page for Coherus news (Ticker: CHRS), a resource for investors and traders seeking the latest updates and insights on Coherus stock.
Coherus Oncology, Inc. reports commercial-stage oncology developments centered on LOQTORZI® (toripalimab-tpzi), an approved next-generation PD-1 inhibitor for recurrent or metastatic nasopharyngeal carcinoma. Company updates also cover its antibody immunotherapy pipeline, including tagmokitug, an anti-CCR8 cytolytic antibody, and casdozokitug, an IL-27 antagonistic antibody, across solid-tumor programs such as liver, prostate, head and neck, colorectal, gastric and esophageal cancers.
Recurring news includes financial results, LOQTORZI revenue commentary, clinical-development updates, strategic partnerships, investor-conference presentations, public common-stock offerings, debt reduction and other capital-structure actions tied to the company's transition from biosimilars to innovative oncology.
Coherus Oncology (Nasdaq: CHRS) will release its second quarter 2026 financial results on Wednesday, August 5, 2026, followed by a management conference call and webcast starting at 5:00 p.m. Eastern Daylight Time. Investors can pre-register online to receive dial-in details and a personal PIN, or access the live and archived webcast via the Coherus investors website.
According to Coherus Oncology, the company uses its investors website for disclosure of material information under Regulation FD. The release also highlights LOQTORZI, an approved PD-1 inhibitor, and mid-stage pipeline candidates tagmokitug and casdozokitug in various solid tumor indications.
Coherus Oncology (Nasdaq: CHRS) and Zumutor Biologics announced a clinical collaboration and supply agreement to evaluate ZM008, an anti-LLT1 monoclonal antibody, in combination with LOQTORZI (toripalimab-tpzi) in a Phase 1 trial (NCT06451497).
The US study has dosed its first patient and will enroll up to 45 patients with multiple solid tumors, assessing safety, tolerability and recommended dose. Coherus supplies LOQTORZI; Zumutor sponsors the trial, and both retain commercial rights to their own compounds.
Coherus Oncology (Nasdaq: CHRS) reported Q1 2026 net revenue from continuing operations of $12.3 million, with LOQTORZI net revenue of $11.8 million, up 61% year over year and down 5% sequentially. Net loss narrowed to $36.9 million from $47.4 million.
Cash, cash equivalents and marketable securities totaled $167.0 million at March 31, 2026. The company raised $53.6 million net via a public offering of 32.89 million shares. Key pipeline updates include full enrollment of the randomized Phase 2 casdozokitug uHCC trial and multiple ongoing Phase 1b tagmokitug combination studies with data readouts expected in 2026.
Coherus Oncology (Nasdaq: CHRS) will release first quarter 2026 financial results after market close on Monday, May 11, 2026.
The company will host a management conference call and webcast starting at 5:00 p.m. Eastern Time on May 11, 2026. A replay and press release will be available at https://investors.coherus.com.
Coherus Oncology (NASDAQ: CHRS) reported full-year and Q4 2025 results, highlighting commercial growth for LOQTORZI, major debt reduction, cash position and pipeline progress. LOQTORZI revenue more than doubled to $40.8M in 2025. Secured and convertible debt was reduced ~90% to $38.8M. Cash and marketable securities totaled $172.1M at year-end. The company reported a 2025 net loss of $183.1M and ongoing R&D investment in tagmokitug and casdozokitug with multiple clinical readouts expected in 2026.
Notable clinical data include a 6-year OS median of 64.8 months vs 33.7 months for chemotherapy in JUPITER-02 (HR 0.62), and a prior Phase 2 casdozokitug CR rate of 17%.
Coherus Oncology (Nasdaq: CHRS) will release its full year and fourth quarter 2025 financial results after market close on Monday, March 9, 2026. A management conference call and webcast will begin at 4:30 p.m. ET the same day, with a replay posted on the company investor website.
Investors can pre-register for dial-in details and PIN, and the press release and related materials will be available on the Coherus investor site before the call.
Coherus Oncology (NASDAQ: CHRS) said senior management will present at two investor conferences in March 2026 with webcasts and replays available on the company investor events calendar.
Presentations: TD Cowen Healthcare Conference on March 4, 2026 at 11:50 AM ET and Citizens Life Sciences Conference on March 10, 2026 at 2:50 PM ET. Replays will be posted for approximately 90 days.
Coherus Oncology (NASDAQ: CHRS) closed an underwritten public offering of 28,600,000 common shares at $1.75 per share on Feb 17, 2026, generating approximately $50.1 million gross proceeds before fees.
The company granted underwriters a 30-day option to purchase up to 4,290,000 additional shares for over-allotments. Proceeds will support commercialization of LOQTORZI, continued clinical programs, working capital and general corporate purposes.
Coherus Oncology (NASDAQ: CHRS) priced an underwritten public offering of 28,600,000 common shares at $1.75 per share, raising approximately $50.1 million in gross proceeds. The company granted a 30-day option for an additional 4,290,000 shares and expects closing on or about February 17, 2026.
Net proceeds are intended to support commercialization of LOQTORZI (toripalimab-tpzi), continue clinical development, and for working capital and general corporate purposes.
Coherus Oncology (NASDAQ: CHRS) announced a proposed underwritten public offering of its common stock on Feb 12, 2026.
Key points: Coherus will offer shares from its effective Form S-3 shelf (File No. 333-291520, filed Nov 13, 2025); underwriters have a 30-day option for up to 15% additional shares. Net proceeds are targeted to support commercialization of LOQTORZI (toripalimab-tpzi), continue clinical development, and for working capital and general corporate purposes. The Offering is subject to market conditions and may not be completed as proposed.